Highlights in Health: From Indigenous Studies to Cancer Trials

This article summarizes recent health news, including Canada's funding for an Indigenous-led oil sands health study, a hung jury in the third Zantac cancer trial, FDA approvals of kidney and brain tumor treatments, and WHO's efforts on polio vaccination in Gaza despite the conflict.

Following is a summary of current health news briefs.

Canada will fund an Indigenous-led study to explore the impact of oil sands on local communities' health, sparked by pollution concerns arising from a tailings leak at an Imperial Oil site. Environment Minister Steven Guilbeault announced Ottawa's commitment of C$12 million over a decade for the Fort Chipewyan Health Study.

In other news, the third trial related to Zantac cancer claims ended in a mistrial as jurors couldn't decide on pharmaceutical company Boehringer Ingelheim's liability in an Illinois man's prostate cancer case. Plaintiff Martin Gross, who alleged the contamination from the drug caused his cancer, may pursue another trial.

The U.S. FDA gave green lights to new treatments from Novartis for kidney disease and Servier for brain tumors, reflecting a positive trend in cancer and rare disease therapies. Meanwhile, WHO's polio vaccination campaign in Gaza faces hurdles due to the conflict in the region.